+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amyloidosis Treatment Market - Global Forecast 2026-2032- Product Image
Amyloidosis Treatment Market - Global Forecast 2026-2032- Product Image
New

Amyloidosis Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 193 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888733
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The amyloidosis treatment market is rapidly evolving, with ongoing innovation in therapies, diagnostics, and care delivery models creating new dynamics and substantial opportunities for strategic investment.

Market Snapshot

The global amyloidosis treatment market is projected to expand from USD 6.13 billion in 2025 to USD 6.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.56%. By 2032, the market is expected to reach USD 10.21 billion. This growth reflects increased adoption of advanced pharmacological modalities and the transition toward precision medicine, catalyzed by heightened diagnostic capabilities and transformative clinical developments.

Amyloidosis Treatment Market Scope & Segmentation

  • Disease Subtypes: Covers AA, AL, hereditary ATTR, and wild-type ATTR. Each subtype presents unique clinical challenges and therapeutic imperatives, influencing treatment selection and care models.
  • Drug Classes: Includes alkylating agents, immunomodulators, monoclonal antibodies, proteasome inhibitors, transthyretin (TTR) silencers, TTR stabilizers, and adjunctive supportive therapies.
  • Administration Routes: Assesses intravenous infusions, oral therapies, subcutaneous injections, and home-based delivery potential.
  • Care Settings: Considers hospital outpatient infusion centers, specialty clinics, and home-care models, each affecting access, adherence, and resource needs.
  • Regions: Americas, Europe Middle East & Africa, and Asia-Pacific. Analysis includes regulatory, payer, and clinical infrastructure factors shaping access and adoption regionally.
  • Technological Advances: Evaluates the impact of RNA-based therapies, monoclonal antibodies, imaging modalities, mass spectrometry-based diagnostics, and biomarker innovation.

Key Takeaways

  • The amyloidosis therapeutic environment is increasingly multifaceted, blending targeted pharmacological approaches with precision diagnostic advances.
  • Recent progress has shifted treatment from supportive care toward modalities capable of modifying disease biology, thus enhancing survival and quality of life.
  • The growing range of pharmacologies requires careful patient stratification, especially as providers balance treatment efficacy, logistics, and long-term tolerability.
  • Technological improvements foster earlier and more accurate diagnosis, enabling more specific therapy matching and reducing heterogeneity in clinical trial cohorts.
  • Home-based and outpatient administration formats are changing care delivery patterns, improving patient experience, and impacting total cost of care.
  • Market access strategies must incorporate both clinical outcomes and real-world effectiveness data to satisfy payer requirements and facilitate broad adoption.

Tariff Impact on Supply Chains and Pricing

Impending U.S. tariff changes in 2025 are poised to introduce new commercial complexity to global amyloidosis supply chains. Manufacturers will need to navigate higher lead times, consider onshore versus offshore production, and potentially reevaluate inventory policies for both biologics and oligonucleotide therapies. Payers may respond to these changes with tighter cost control and increased scrutiny during reimbursement negotiations. In parallel, tariff incentives could spur investment in regional manufacturing, driving long-term supply resilience. Biopharma leaders are expected to reassess operational strategies to balance supply continuity with pricing pressures and evolving program logistics.

Methodology & Data Sources

This report integrates peer-reviewed clinical literature, regulatory filings, expert interviews, guideline statements, and conference presentations. Quantitative market estimations derive from randomized trials, real-world registry data, and operational risk analysis. Qualitative insight from clinical, payer, and supply-chain experts contextualizes treatment trends.

Why This Report Matters

  • Guides decision-makers to align clinical innovation with operational and market-access strategies for sustainable patient impact.
  • Delivers actionable intelligence on regional variability in adoption, regulation, and clinical infrastructure.
  • Equips organizations to anticipate supply-chain disruptions and optimize commercial pathways amid evolving policy landscapes.

Conclusion

Strategic alignment of clinical, operational, and access initiatives is essential for transforming therapeutic innovation in amyloidosis into measurable patient outcomes. Organizations that anticipate market shifts and invest in adaptability will be best positioned to capture emerging opportunities in this dynamic field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Amyloidosis Treatment Market, by Treatment Type
8.1. Pharmacological Treatment
8.1.1. Alkylating Agents
8.1.2. Immunomodulators
8.1.3. Monoclonal Antibodies
8.1.4. Proteasome Inhibitors
8.1.4.1. Bortezomib
8.1.4.2. Carfilzomib
8.1.4.3. Ixazomib
8.1.5. TTR Silencers
8.1.5.1. Inotersen
8.1.5.2. Patisiran
8.1.6. TTR Stabilizers
8.1.6.1. Acoramidis
8.1.6.2. Tafamidis
8.2. Stem Cell Transplantation
8.3. Supportive Therapy
9. Amyloidosis Treatment Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Amyloidosis Treatment Market, by Drug Class
10.1. Alkylating Agents
10.2. Immunomodulators
10.3. Monoclonal Antibodies
10.4. Proteasome Inhibitors
10.4.1. Bortezomib
10.4.2. Carfilzomib
10.4.3. Ixazomib
10.5. TTR Silencers
10.5.1. Inotersen
10.5.2. Patisiran
10.6. TTR Stabilizers
10.6.1. Acoramidis
10.6.2. Tafamidis
11. Amyloidosis Treatment Market, by Amyloidosis Type
11.1. AA
11.2. AL
11.3. Hereditary ATTR
11.4. Wild-Type ATTR
12. Amyloidosis Treatment Market, by End User
12.1. Home Care
12.2. Hospital
12.3. Specialty Clinic
13. Amyloidosis Treatment Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Amyloidosis Treatment Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Amyloidosis Treatment Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Amyloidosis Treatment Market
17. China Amyloidosis Treatment Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbvie, Inc.
18.6. Acrotech Biopharma, Inc
18.7. Alexion Pharmaceuticals
18.8. Alnylam Pharmaceuticals Inc.
18.9. Arcturus Therapeutics, Inc.
18.10. Astellas Pharma, Inc.
18.11. AstraZeneca PLC
18.12. Attralus, Inc.
18.13. BridgeBio Pharma, Inc.
18.14. Bristol-Myers Squibb Company
18.15. Corino Therapeutics, Inc.
18.16. GlaxoSmithKline PLC
18.17. Ionis Pharmaceuticals, Inc.
18.18. Johnson & Johnson Services Inc
18.19. Merck & Co., Inc.
18.20. Neurimmune AG
18.21. Oncopeptides AB
18.22. Pfizer Inc.
18.23. Proclara Biosciences Inc.
18.24. Prothena Corporation PLC
18.25. Regeneron Pharmaceuticals Inc.
18.26. SOM INNOVATION BIOTECH, SA,
18.27. Sorrento Therapeutics, Inc.
18.28. Spectrum Pharmaceuticals, Inc.
18.29. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 185. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 186. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 187. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 188. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 189. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 190. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 192. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 193. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 194. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 195. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 196. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 212. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 213. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 214. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 215. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 216. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 219. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 220. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 221. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 222. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 237. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 239. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 240. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 241. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 242. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 243. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 245. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 246. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 247. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 248. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 249. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 250. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 251. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 252. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 253. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 254. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 255. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 256. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 257. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 258. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 259. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 260. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 261. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 262. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 277. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 278. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 279. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 280. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 281. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 282. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 283. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 284. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 285. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 286. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 287. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 288. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 289. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 290. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 291. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 292. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 293. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 294. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 295. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 296. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 297. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 298. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 299. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 300. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 301. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 303. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 304. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 305. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 306. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 307. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 308. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 310. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 311. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 312. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 313. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
TABLE 314. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 315. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 316. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 317. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 318. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 319. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
TABLE 320. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
TABLE 321. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
TABLE 322. UNITED S

Companies Mentioned

The key companies profiled in this Amyloidosis Treatment market report include:
  • Abbvie, Inc.
  • Acrotech Biopharma, Inc
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals Inc.
  • Arcturus Therapeutics, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Attralus, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Corino Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc
  • Merck & Co., Inc.
  • Neurimmune AG
  • Oncopeptides AB
  • Pfizer Inc.
  • Proclara Biosciences Inc.
  • Prothena Corporation PLC
  • Regeneron Pharmaceuticals Inc.
  • SOM INNOVATION BIOTECH, SA,
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.59 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.21 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Amyloidosis Market Report and Forecast 2025-2034 - Product Image

Amyloidosis Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Amyloidosis Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care), by End Use ( Hospitals & Clinics), by Region, and Segment Forecasts, 2025-2033 - Product Image

Amyloidosis Treatment Market Size, Share & Trends Analysis Report by Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care), by End Use ( Hospitals & Clinics), by Region, and Segment Forecasts, 2025-2033

  • Report
  • 130 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market Report 2025 - Product Image

Transthyretin Amyloidosis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Amyloidosis Treatment Market - Product Image

Amyloidosis Treatment Market

  • Report
  • 100 Pages
  • Global
From

About the Amyloidosis‎ Drug Market

Amyloidosis is a rare endocrine and metabolic disorder caused by the accumulation of abnormal proteins in the body's organs and tissues. Treatment for amyloidosis typically involves a combination of drugs, including chemotherapy, corticosteroids, and immunosuppressants. The amyloidosis drug market is expected to grow in the coming years due to the increasing prevalence of the disease and the development of new drugs. The amyloidosis drug market is highly competitive, with a number of companies developing and marketing drugs for the treatment of the disease. Some of the major players in the market include Pfizer, Novartis, Sanofi, Merck, and Johnson & Johnson. These companies are focusing on developing new drugs and expanding their product portfolios to meet the growing demand for amyloidosis treatments. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.